Concepedia

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

Leukemia Research · 2007 · 99 citations · 35 references

DOIFull text

Open access

Concepts

References

35

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

, , +17

Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis

Sergio Cortelazzo, Guido Finazzi, Marco Ruggeri et al. · New England Journal of Medicine · 1995 · 847 citations · Full text

, , +11

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian et al. · PubMed · 2000 · 665 citations

, , +11

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity

Rick A. Finch, Mao‐Chin Liu, Susan P. Grill et al. · Biochemical Pharmacology · 2000 · 367 citations

, , +8

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

Varsha Gandhi, Elihu H. Estey, M Keating et al. · Journal of Clinical Oncology · 1993 · 335 citations

, , +17